LONDON, UK / ACCESSWIRE / July 10, 2020 / Hemogenyx Pharmaceuticals plc is pleased to announce that its U.S. subsidiary will be renamed Hemogenyx Pharmaceuticals LLC in order to align the Company’s names across entities and countries, and should always be referred to as Hemogenyx Pharmaceuticals instead of Hemogenyx by itself. The company will continue to conduct preclinical and clinical stage research and development activities to develop its own products and therapies, including therapies and treatments for blood and autoimmune diseases and viral infections. Hemogenyx Pharmaceuticals LLC will remain located at its state-of-the-art research facility in New York City.
Hemogenyx Pharmaceuticals plc
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
Peter Redmond, Director
SP Angel Corporate Finance LLP
Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited
Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries
Tel: +1 (323) 646-3249
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals plc
View source version on accesswire.com: https://www.accesswire.com/596718/Hemogenyx-Pharmaceuticals-plcAnnounces-US-Subsidiary-Change-of-Name